Ahmadu Bello University (ABU) and AMA Pharmaceutical Company (AMA-MED) have expressed their intention to establish a strategic partnership...
Ahmadu Bello University (ABU) and AMA Pharmaceutical Company (AMA-MED) have expressed their intention to establish a strategic partnership focused on drug development and the commercialisation of research outputs.
AMA-MED, the largest pharmaceutical company in Northern Nigeria and based in Kaduna, is renowned for producing high-quality, life-saving intravenous (IV) fluids. Since its establishment in 2019, the company has been at the forefront of medical manufacturing innovation.
The collaboration aligns with President Bola Ahmed Tinubu’s Executive Order on raw materials for pharmaceutical production, signed last year, and is expected to enhance local production of healthcare products while reducing production costs.
The partnership discussions began when ABU Vice-Chancellor, Prof. Adamu Ahmed, visited AMA-MED in Kaduna for the Students Industrial Work Experience Scheme (SIWES) placement. Prof. Ahmed was impressed by the company’s state-of-the-art facility, equipped with advanced AFFS technology, as well as its commitment to continuous innovation.
During the visit, both parties explored opportunities for collaboration across various aspects of pharmaceutical development, as well as the potential to promote the commercialisation of research outputs from ABU’s Faculty of Pharmaceutical Sciences and related departments. The partnership is envisioned to bridge the gap between academia and industry, enhancing the competitiveness of local drug manufacturers.
The collaboration process was further consolidated during a recent return visit to ABU, Zaria, by AMA-MED Founder, Alhaji Abdullahi Musa.
Prof. Ahmed expressed confidence that the partnership would significantly strengthen the university’s engagement with industry and facilitate the translation of research into commercially viable healthcare solutions. He noted that ABU is actively seeking collaborations with industry partners to drive commercialisation and that his recent visits to the University of Glasgow and the University of Salford in the United Kingdom have opened additional avenues for research collaboration and industrial linkages.
No comments